AstraZeneca and Sanofi tout breakthrough in €645M alliance against leading cause of infant death
After 23 years, a new treatment for one of the leading causes of infant death may be on the horizon.
AstraZeneca and Sanofi announced Monday that an experimental antibody, nirsevimab, successfully prevented infants from developing RSV infections that required any type of medical attention. The two Big Pharmas offered few details about the large Phase III trial, but said the results came sooner than expected and that they would file for approvals around the globe next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.